Physician profile
Christopher Graham
NPI 1962864538
$9,095.31
in general payments reported to CMS, 2019-2025
29 companies · $3,804 in 2025
The $3,804 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.00 · 2020: $267 · 2021: $1,236 · 2022: $1,359 · 2023: $2,286 · 2024: $54.64 · 2025: $3,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,575 · Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,575.00 |
| Food and Beverage | $569.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,052.57 | 2021-2025 | |
| Adc Therapeutics America, INC. | $2,146.92 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $435.19 | 2021-2022 | |
| Seagen INC. | $239.04 | 2019-2022 | |
| Kite Pharma, INC. | $213.57 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $202.75 | 2022-2023 | Opdivo, Opdualag |
| Eisai INC. | $200.31 | 2021-2022 | |
| Daiichi Sankyo INC. | $173.16 | 2022 | |
| Merck Sharp & Dohme LLC | $157.94 | 2021-2022 | |
| Astellas Pharma US INC | $152.58 | 2020-2022 | |
| Genentech USA, INC. | $140.78 | 2021-2022 | |
| Janssen Biotech, INC. | $135.58 | 2021-2024 | Tecvayli, Darzalex, Talvey |
| Janssen Scientific Affairs, LLC | $128.00 | 2022 | |
| Dova Pharmaceuticals | $125.00 | 2021 | |
| Amgen INC. | $113.07 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $71.87 | 2021 | |
| Celgene Corporation | $71.66 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $64.42 | 2023 | Epkinly, Imbruvica |
| Novartis Pharmaceuticals Corporation | $58.80 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $40.07 | 2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Sobi, INC | $35.31 | 2022 | |
| Genzyme Corporation | $28.21 | 2020 | |
| Karyopharm Therapeutics INC. | $23.63 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.00 | 2022 | |
| G1 Therapeutics, INC. | $15.50 | 2022 | |
| Gilead Sciences, INC. | $15.14 | 2022 | |
| Abbvie INC. | $13.25 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.07 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.